From the *Department of Pharmacy, Division of Pediatric Infectious Diseases, Prisma Health Children’s Hospital—Midlands, Columbia, South Carolina
†Department of Pediatrics, Division of Pediatric Infectious Diseases, Prisma Health Children’s Hospital—Midlands, Columbia, South Carolina
‡Department of Pediatrics, Division of General and Hospital Pediatrics, Prisma Health Children’s Hospital—Midlands, Columbia, South Carolina
§Adaptive Phage Therapeutics, Gaithersburg, Maryland
¶Department of Genomics & Bioinformatics, Biological Defense Research Directorate, Naval Medical Research Center, Frederick, Maryland.
Accepted for publication September 1, 2022
No funding was received for this single patient emergency IND but the part of the work conducted by NMRC was supported by Work Unit #A1417
Dr. Mike Brownstein has equities in Adaptive Phage Therapeutics.
All the authors contributed significantly to the composition and editing of the article. A.G., R.D., A.B., and J.H. were responsible for direct patient care and treatment. J.F., B.B., and M.B. through Adaptive Phage Therapeutics and the Navy Medical Research Center, provided a phage cocktail as well as clinical guidance.
The views expressed in this journal article reflect the results of research conducted by the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, nor the United States Government.
All the authors have read and approved the article. This article has not been previously published and is not under consideration for publication elsewhere.
This article discusses the use of phage therapy which is not an FDA approved agent.
B.B. is a federal employee of the United States government. This work was prepared as part of his official duties. Title 17 U.S.C. 105 provides that “copyright protection under this title is not available for any work of the United States Government.” Title 17 U.S.C. 101 defines a U.S. Government work as work prepared by a military service member or employee of the U.S. Government as part of that person’s official duties.
All appropriate procedures, according to the FDA and our institutional review board, were followed. Written informed consent was obtained from the patient’s legal guardians.
Address for correspondence: Andrew B. Gainey, PharmD, Prisma Health Children’s Hospital–Midlands, 7 Medical Park Rd, Columbia, SC 29203. E-mail: [email protected]h.org; Robert Daniels, PharmD, Prisma Health Children’s Hospital–Midlands, 7 Medical Park Rd, Columbia, SC 29203. E-mail: [email protected].
